
Here is a list of some recent trials that launched within the cancer space in November.

Ryan McDonald, Associate Editorial Director for CURE®, has been with the team since February 2020 and has previously covered medical news across several specialties prior to joining MJH Life Sciences. He is a graduate of Temple University, where he studied journalism and minored in political science and history. He considers himself a craft beer snob and would like to open a brewery in the future. During his spare time, he can be found rooting for all major Philadelphia sports teams. Follow Ryan on Twitter @RMcDonald11 or email him at [email protected].

Here is a list of some recent trials that launched within the cancer space in November.

On social media, CURE® recently asked its readers to share their thoughts on what they wish they could change about cancer care.

On social media, CURE® recently asked its readers to share what first steps they took after they received their cancer diagnosis and if there were any resources that they found particularly helpful.

Topline results from the phase 3 PROTECTIVE-2 study demonstrated that plinabulin in combination with Neulasta (pegfilgrastim) significantly improved the prevention of chemotherapy-induced neutropenia, compared to the standard of care alone.

“The concept that people have sometimes is that they put doctors on a pedestal, which is fine,” Bud Green said. And they somehow think that all doctors are kind of the same, and they're all as good. And I think that they need to see that different specialties look at things from a different perspective.

In this episode of the “CURE Talks Cancer” podcast, we spoke with a couple that has been married for 41 years about their journey as patient and caregiver during two bouts of triple-negative breast cancer. The couple, Janice and Rex Cowden, also give others facing similar situations advice on how to persevere together.

Legendary “Jeopardy!” host Alex Trebek died on Sunday after receiving a pancreatic cancer diagnosis in March 2019. He was 80.

Patients with resected, high-risk, stage 3 melanoma who were randomized to receive Keytruda (pembrolizumab) achieved a three-year recurrence-free survival rate of 63.7% compared to 44.1% in patients randomized to placebo.

In an interview with CURE®, Dr. Phillip J. Koo defines what theranostics is, discusses the treatment’s potential and answers questions patients may have regarding its safety.

From a Canadian man shaving his moustache for the first time in nearly 50 years to participate in Movember to HGTV’s “Flip or Flop” host Tarek El Moussa discussing his journey with testicular and thyroid cancer, here’s what’s happening in the cancer landscape this week.

In this episode of the “CURE Talks Cancer” podcast, we spoke with the dental director in the oral health program at the Rhode Island Department of Health about the oral health issues that can occur as a result of a patient’s cancer treatment.

On social media, CURE® recently asked its readers to give a shout out to their ‘cancer hero’: the person or persons who they met while on their cancer journey and they now admire.

Here is a list of some recent trials that launched within the cancer space in October.

The FDA granted a priority review to the biologics license application and new drug application for the combination of Opdivo and Cabometyx for patients with advanced kidney cancer.

A roundup of the latest news and updates for patients with myeloma from CURE®.

The FDA’s approval or Opdivo (nivolumab) and Yervoy (ipilimumab) for the frontline treatment of patients with unresectable malignant pleural mesothelioma was desperately needed, says a thoracic oncologist at Memorial Sloan Kettering Cancer center. However, some questions remain.

On social media, CURE® recently asked its readers to share how cancer has affected their careers.

From “The Wanted” singer Tom Parker announcing he has been diagnosed with stage 4 glioblastoma and is undergoing treatment, to a Houston-area father receiving treatment for leukemia surprising his daughter on her wedding day, here’s what’s happening in the cancer landscape this week.

Two physicians, a nurse and a patient advocate were honored during CURE®’s first ever Lung Cancer Heroes program.

In this episode of the “CURE Talks Cancer” podcast, we spoke with an expert from Dana-Farber Cancer Institute in Boston about the results of an early-phase clinical trial that assessed the efficacy of a combination therapy in the frontline setting in patients with CLL aged 65 years and younger, as well as a pendulum swing in research over the last decade.

Data from the trial that led to the FDA approval demonstrated that Keytruda reduced the risk of progression or death in patients with relapsed or refractory classical Hodgkin lymphoma by 35%, compared to Adcetris.

The average overall survival for patients who reported consuming four or more cups of coffee per day prior to trial enrollment was 39 months.

On social media, CURE® recently asked its readers to share their thoughts on the month of “Pinktober”.

Cancer-treatment induced dry mouth can lead to several severe health issues. Here, Dr. Randy Kimple discusses how the side effect can lead to dental health issues, as well as other health consequences including pneumonia.

Outside of drinking plenty of water or avoiding foods that can induce dry mouth, Dr. Randy Kimple notes that there are very few effective treatments for patients who experience cancer treatment-related dry mouth.

“Collectively, our mature data provide the most definitive evidence supporting current guidelines, that HDT/ASCT should not be offered to unselected patient(s) (with follicular lymphoma) in the frontline setting,” the authors wrote.

Legendary Van Halen lead guitarist, Eddie Van Halen, died on Tuesday from cancer. He was 65.

On social media, CURE® recently asked its readers to share the most important lesson cancer taught them.

The Food and Drug Administration’s approval of Opdivo in combination with Yervoy for patients with unresectable malignant pleural mesothelioma marks the first new systemic therapy approved in more than 15 years in this setting.

On social media, CURE® recently asked its readers to share how an oncology nurse has helped them on their cancer journey.